A real-world clinical study of carrelizumab combined with ablation in the treatment of primary liver cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034952

Enrollment

Unknown

Registered

2020-07-25

Start date

2020-08-30

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Patients with unresectable primary liver cancer that meets the clinical diagnostic criteria of the Standards for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma (2019 Edition) or confirmed by histopathological or cytological examination; 3. At least 1 measurable lesion according to the mRECIST standard; 4. The investigators determine that the patient can be administered Camrelizumab; 5. The researcher determined that the patient can receive ablation; 6. Signed informed consent and agreed to collect the information of patients.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients with hypersensitivity to the active ingredients of Camrelizumab or any of the excipients listed in its ingredients; 3. Patients who investigators suggest not be included.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Secondary

Measure	Time frame
OS;ORR;1 year OS rate;DCR;Safety;	—

Countries

China

Contacts

Public ContactZhe Tang

The Second Affiliated Hospital Zhejiang University

8xi@zju.edu.cn+86 13757118212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026